Physician profile
Geoffrey Groff
NPI 1730184995
$8,988.49
in general payments reported to CMS, 2019-2025
53 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,240 · 2020: $1,218 · 2021: $2,373 · 2022: $1,058 · 2023: $910 · 2024: $920 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,187.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $692.16 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $677.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $647.45 | 2019-2023 | Belsomra, Steglujan, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.08 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $568.92 | 2019-2024 | Farxiga, Airsupra |
| Pfizer INC. | $465.47 | 2019-2025 | |
| Abbvie INC. | $436.97 | 2019-2023 | |
| Astellas Pharma US INC | $430.21 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $294.76 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.57 | 2019-2022 | |
| Glaxosmithkline, LLC. | $261.60 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $217.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $208.27 | 2019-2022 | |
| Abbott Laboratories | $205.66 | 2021-2023 | Proclaim |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Groff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.